# US 2013/0253045 A1 · Prodrugs of Substituted 1,3-Dioxanes and Their Uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253045 A1
- Document ID: US20130253045A1
- Status: Published application
- Kind: A1
- Application number: 13/787,289
- Filed: 2013-03-06
- Published: 2013-09-26
- Earliest claimed: 2007-01-18
- Assignees: Evolva SA
- Inventors: Peteris Alberts; Alexandra Santana Sorensen
- Web page: https://patentgrep.com/patent/US20130253045A1

## CPC

- C07D 319/06: not condensed with other rings
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/77: of oxiranes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.

## Claims

### Claim 1

A compound of formula (III)
where X is hydrogen, halogen, cyano, nitro, hydroxyl, haloalkyl, alkyl, or O—R where R is a lower alkyl group,
n is 0, 1, 2, 3, 4, or 5;
Z1 and Z2 are independently selected to be O, N, or S, and Rp and Rp′ are independently selected from H, lower alkyl, or a progroup.

### Claim at position 2

2-9. (canceled)

### Claim 10

A method of inhibiting a thromboxane A2 or a peroxisome proliferator-activated receptor, the method comprising contacting the receptor with a compound of formula (III)
where X is hydrogen, halogen, cyano, nitro, hydroxyl, haloalkyl, alkyl, or O—R where R is a lower alkyl group,
n is 0, 1, 2, 3, 4, or 5;
Z1 and Z2 are independently selected to be O, N, or S, and Rp and Rp′ are independently selected from H, lower alkyl, or a progroup.

### Claim at position 4

11-15. (canceled)

### Claim 16 (depends on 1)

A method for treating or preventing a disorder associated with a thromboxane A2 or peroxisome proliferator-activated receptors, the method comprising: administering to a subject an effective amount of a compound of claim 1 or acceptable salts, N-oxides, hydrates, or solvates thereof; and pharmaceutically-acceptable carrier or diluent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the disorder is selected from the group consisting of diabetes, cancer, inflammation, AIDS, metabolic syndrome, obesity, pre-diabetes, hypertension and dyslipidemia.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject is a human.

### Claim at position 8

19-23. (canceled)

### Claim 24 (depends on 16)

The method of claim 16, wherein the disorder is selected from the group consisting of myocardial infarction, thrombosis, thrombotic disorders, pulmonary hypertension, atherosclerosis, diabetic nephropathy, retinopathy, peripheral arterial disease, lower limb circulation, pulmonary embolism, thrombus formation, stent-triggered thrombus formation, stent-triggered hyperplasia, septic shock, preeclampsia, asthma, allergic rhinitis, tumour angiogenesis and metastasis.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

The composition according to claim 25, wherein the composition is for delayed-, modified-, sustained-, or controlled-release of the compound.

### Claim 28 (depends on 27)

The composition according to claim 27 comprising at least one release rate modifier.

### Claim 29 (depends on 28)

The composition according to claim 28, wherein said release rate modifier is selected from the group consisting of hydroxypropylmethyl cellulose, methyl cellulose, sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, polyethylene oxide, cremophor, corn oil glyceride and propylene glycol, Xanthan gum, Carbomer, ammonio methacrylate copolymer, hydrogenated castor oil, carnauba wax, paraffin wax, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, methacrylic acid copolymer and mixtures thereof.
